Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
MGD007 is a humanized DART® molecule that recognizes both the glycoprotein A33 antigen, or gpA33, and CD3. The gpA33 antigen is expressed on gastrointestinal tumors, including more than 95% of human colon cancers. MGD007 was designed to redirect T cells, via their CD3 component, to kill gpA33-expressing cells.
MGD007 is being tested in patients with colorectal cancer in a Phase 1 clinical study in combination with MGA012.
MacroGenics retains full worldwide rights to MGD007.